FDA Grants Neladalkib Accelerated Approval

Company Nuvalent Event Type FDA accelerated approval Modality Small molecule kinase inhibitor Asset Neladalkib Target ALK Disease Area ALK-positive non-small cell lung cancer Summary FDA granted accelerated approval to oral ALK inhibitor neladalkib for specified previously treated ALK-positive advanced NSCLC. In ALKOVE-1, confirmed response was…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *